Invasive fungal infections in children with cancer and severe aplastic anemia in nine hospitals from PINDA Network, Chile. 2016-2020

Simple item page
dc.contributor.authorGutierrez, Valentina
dc.contributor.authorContardo, Veronica
dc.contributor.authorde la Maza, Veronica
dc.contributor.authorClaverie, Ximena
dc.contributor.authorSalgado, Carmen
dc.contributor.authorZubieta, Marcela
dc.contributor.authorSilva, Beatriz
dc.contributor.authorTorres, Juan P.
dc.contributor.authorGreppi, Claudia
dc.contributor.authorVenegas, Marcela
dc.contributor.authorMartinez, Daniela
dc.contributor.authorAlvarez, Ana M.
dc.contributor.authorLabrana, Yenis
dc.contributor.authorDiaz, Paulina
dc.contributor.authorDucasse, Karen
dc.contributor.authorInostroza, Tamara
dc.contributor.authorCordova, Marcela
dc.contributor.authorSantolaya, Maria E.
dc.date.accessioned2025-01-20T17:14:16Z
dc.date.available2025-01-20T17:14:16Z
dc.date.issued2023
dc.description.abstractBackground: Invasive fungal infections (IFIs) are an important cause of morbidity and mortality in pediatric oncology patients and severe aplastic anemia (SAA). Aim: To describe the epidemiology of IFI from 2016 to 2020 in children with cancer and SAA to assess the indication of antifungal prophylaxis. Methods: Multicenter, retrospective study of IFIs in pediatric oncology patients and SAA. Probable and proven IFIs were included. Results: Over the 5-year period, 57 IFIs were found, median age 9 years, 70% were proven and 30% were probable. Yeast infections were 42% and mold infections 56%. The most frequent infection sites were lung 38%, blood 36% and rhinosinusal 21%. The total IFI frequency was 5.4%, 21% in SAA, 10% in acute myeloid leukemia (AML), 6.9% in relapsed AML, 5.4% in relapsed acute lymphoblastic leukemia (ALL), 3.8% in ALL. Mold infections were predominant in AML, relapsed AML, and SAA. IFIs mortality was 11%. Conclusion: Frequency of IFI was consistent with the literature. We strongly recommend antifungal prophylaxis against mold infections in patients with SAA, AML, and relapsed AML. Would consider in high risk ALL relapse in induction chemotherapy.
dc.fuente.origenWOS
dc.identifier.doi10.4067/s0716-10182023000400360
dc.identifier.eissn0717-6341
dc.identifier.issn0716-1018
dc.identifier.urihttps://doi.org/10.4067/s0716-10182023000400360
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/91285
dc.identifier.wosidWOS:001127852600001
dc.issue.numero4
dc.language.isoen
dc.pagina.final369
dc.pagina.inicio360
dc.revistaRevista chilena de infectologia
dc.rightsacceso restringido
dc.subjectinvasive fungal infection
dc.subjectfebrile neutropenia
dc.subjectantifungal prophylaxis
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleInvasive fungal infections in children with cancer and severe aplastic anemia in nine hospitals from PINDA Network, Chile. 2016-2020
dc.typeartículo
dc.volumen40
sipa.indexWOS
sipa.trazabilidadWOS;2025-01-12
Files
Collections
Artículos de revistas